NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
Clinical Trials
16 trialsNCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03237377 2025-10-14
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04287894 2024-11-06
Induction
The Netherlands Cancer Institute
Phase 1 Terminated
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT02616185 2023-11-02
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Pfizer
Phase 1 Terminated
NCT03963414 2023-08-28
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Phase 1 Terminated
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT03275597 2023-05-15
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
University of Wisconsin, Madison
Phase 1 Terminated
NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT03081923 2021-05-14
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT03234153 2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2 Terminated
NCT00702923 2019-11-21
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
University of Wisconsin, Madison
Phase 1 Terminated
NCT00897312 2016-04-25
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Vanderbilt-Ingram Cancer Center
Terminated
NCT00585000 2012-06-06
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
AstraZeneca
Phase 1 Terminated